Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: A retrospective Turkish oncology group (TOG) study

Basit Öğe Kaydı
dc.authorid0000-0002-0443-6966
dc.authorid0000-0002-0077-6971
dc.contributor.authorBilici, Ahmet
dc.contributor.authorKoca, Sinan
dc.contributor.authorKaraağaç, Mustafa
dc.contributor.authorAydın Göktaş, Sabin
dc.contributor.authorEraslan, Emrah
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorOcak, Birol
dc.contributor.authorGöksu, Sema Sezgin
dc.contributor.authorPaydaş, Semra
dc.contributor.authorAkgül, Fahri
dc.contributor.authorDerin, Sümeyye
dc.contributor.authorErgün, Yakup
dc.date.accessioned2024-02-22T08:29:38Z
dc.date.available2024-02-22T08:29:38Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractAim: Description of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS). Patients and methods: This multicenter study is based on retrospective review of hospital medical records of patients (? 18 years) treated with pazopanib for non-adipocytic metastatic STS at 37 Oncology clinics across Turkey. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated with further analysis of data on the three most common histological subtypes (leiomyosarcoma [LMS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma [SS]) in the cohort. Results: Data of 552 adults (57.6% women, median age: 52 years) were analyzed. DCR and ORR were 43.1% and 30.8%, respectively. Median PFS was 6.7 months and OS was 13.8 months. For LMS, UPS and SS, median PFSs were 6.1, 5.9 and 7.53 months and median OSs were 15.03, 12.87 and 12.27 months, respectively. ECOG ? 2 was associated with poor PFS and OS. Liver metastasis was only a factor for progression. Second-line use of pazopanib (vs. front-line) was associated with better PFS, its use beyond third line predicted worse OS. Adverse events (AE) occurred in 82.7% of patients. Most common AEs were fatigue (58.3%) and anorexia (52.3%) which were graded as ? 3 in 8.2% and 7.4% of patients, respectively. Conclusion: Pazopanib is effective and well-tolerated in treatment of non-adipocytic metastatic STS. Its earlier use (at second-line), good performance status may result in better outcomes. Worldwide scientific collaborations are important to gain knowledge on rarer STS subtypes by conducting studies in larger patient populations.
dc.identifier.citationBilici, A., Koca, S., Karaağaç, M., Aydın Göktaş, S., Eraslan, E., Kaplan, M. A. ... Ergün, Y. (2023). Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: A retrospective Turkish oncology group (TOG) study. Journal of Cancer Research and Clinical Oncology, 149(11), 8243-8253. https://dx.doi.org/10.1007/s00432-023-04766-3
dc.identifier.doi10.1007/s00432-023-04766-3
dc.identifier.endpage8253
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue11
dc.identifier.pmid37067546
dc.identifier.scopus2-s2.0-85152801829
dc.identifier.scopusqualityQ1
dc.identifier.startpage8243
dc.identifier.urihttps://dx.doi.org/10.1007/s00432-023-04766-3
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12302
dc.identifier.volume149
dc.identifier.wos000972021200003en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBilici, Ahmet
dc.institutionauthorAydın Göktaş, Sabin
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofJournal of Cancer Research and Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectPazopanib
dc.subjectSoft Tissue Sarcoma
dc.subjectTargeted Therapy
dc.subjectSynovial Sarcoma
dc.subjectLeiomyosarcoma
dc.subjectMetastatic Soft Tissue Sarcoma
dc.titleReal-world outcomes of pazopanib in metastatic soft tissue sarcoma: A retrospective Turkish oncology group (TOG) study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Bilici-Ahmet-2023.pdf
Boyut:
1.15 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu